->

Ukwelashwa kwe-CAR T-Cell kwa-Israyeli

 

Xhumana nathi ukuze uthole izinsiza ezibekiwe.

QALISA

I-CAR T cell therapy isiphenduke indlela entsha yokwelapha izinhlobo eziningi zomdlavuza, futhi u-Israel wenze inqubekelaphambili enkulu kule ndawo. Izikhungo zezokwelapha zakwa-Israel bezilokhu zisemaphethelweni ocwaningo nokuthuthukiswa kwe-CAR T cell therapy, zinikeza iziguli ezinomdlavuza wegazi ezingazange zisabele kwezinye izindlela zokwelapha ithemba. Ososayensi bakwa-Israel baye basiza ekudaleni nasekwenzeni amaseli e-CAR T, athuthukise ukusebenza kwawo nokuphepha kwawo. I-CAR T cell therapy isetshenziswe ngempumelelo ezigulini zasezibhedlela zakwa-Israel njengeSheba Medical Centre, isibhedlela saseTel Aviv, kanye neHadassah Medical Centre. Lokhu kuye kwaholela ekukhululweni okumangalisayo kanye namazinga aphezulu okufa. I-Israel isabaluleke kakhulu ekuqhubekeleni phambili kokwelashwa kwe-CAR T cell, okunikeza iziguli ezinomdlavuza emhlabeni wonke ithemba elisha.

Ukwelashwa kwe-CAR T-Cell kwa-Israel - Intuthuko yakamuva

 

I-CAR T cell therapy, uhlobo olusha lwe-immunotherapy eyenza elikhulu emkhakheni wokunakekelwa komdlavuza, yisibonelo esihle. Izibhedlela ezidumile nezikhungo zokufunda kwa-Israel bezihamba phambili ekuthuthukiseni nasekusebenziseni lolu hlelo olusha lokwelapha, okunikeza ithemba kubantu abanezinhlobo ezahlukene zomdlavuza. Ukwelashwa kwe-CAR T-Cell kwa-Israyeli isiyatholakala ezibhedlela eziningi.

The ISaba Medical Centre ingenye yezindawo ezinhle kakhulu kwa-Israel yokuthola ukwelashwa kwe-CAR T cell. Yakha i-Center for Cellular immunotherapy, ephethe ukwenza kanye nokukhipha okomuntu siqu Ukwelashwa kwamaseli e-CAR T. Ithimba lochwepheshe baseSheba lenze inqubekelaphambili emangalisayo ekusizeni abantu nge umdlavuza wegazi njenge-leukemia kanye ne-lymphoma. Iziguli ezivela emhlabeni wonke ezifuna ukwelashwa okuthuthukisiwe ziza kuzo ngenxa yolwazi lwazo kanye nezinsiza ezisezingeni eliphezulu.

Enye indawo ebalulekile i-Hadassah Medical Centre e-Jerusalem, ebilokhu yenza ucwaningo oluningi nge-CAR T cell therapy. Umgomo wabo oyinhloko kube ukusiza izingane ezine-acute lymphoblastic leukemia (YONKE) esezibuyile noma ezingasabeli ekwelashweni. Izindaba zempumelelo ezivela ku-Hadassah zinikeze ithemba emindenini ebhekene nezikhathi ezinzima, njengoba ukwelashwa kwe-CAR T cell kungase kube umugqa wempilo walabo abanokukhetha okuncane kokwelashwa.

Eminyakeni yamuva nje, ukwelashwa kwe-CAR T cell kwenze inqubekelaphambili enkulu kwa-Israel. Abacwaningi bebefuna izindlela zokwenza izindlela zokwelapha zisebenze kangcono futhi zisize abantu abaningi. Okunye kwalokhu ukusetshenziswa kwamaseli e-CAR T anezinhloso ezimbili ezihlukene. Ngokulandela ama-antigen amaningi ngasikhathi sinye, le ndlela ihlose ukwenza ukwelashwa kuphumelele kakhulu futhi kunciphise ingozi yokuphunyuka kwe-antigen, okulapho amangqamuzana omdlavuza egwema ukubonwa amaseli e-CAR T.

Futhi, ososayensi bakwa-Israel bebebheka izindlela ezintsha zokwelapha izimila eziqinile, obekunzima ukwelapheka kunezifo ze-hematological esikhathini esidlule. Abacwaningi baseTel Aviv Sourasky Medical Centre bebehlola amaseli e-CAR T ashintshiwe ukuze akhiqize ama-molecule engeziwe angawenza abe ngcono ekubulaleni izimila eziqinile. Imiphumela yangaphambi kwesikhathi ibukeka imihle, okwenza abantu babe nethemba lokuthi ukwelashwa kwe-CAR T cell kungaba yigxathu elikhulu eliya phambili ekwelapheni izimila eziqinile.

Ukwelashwa kwe-CAR T cell kuyishintshile indlela umdlavuza olashwa ngayo, kunikeza iziguli izindlela ezintsha nethemba elisha. Kwa-Israel, izibhedlela ezihamba phambili nezikhungo zokufunda zilokhu zicindezela imikhawulo yalokhu kwelashwa, zizama ukulenza lisebenze kangcono futhi lisize abantu abaningi. Njengoba ucwaningo luya phambili, ukwelashwa kwe-CAR T cell cishe kuzoba okubaluleke kakhulu kwa-Israel nasemhlabeni jikelele ekulweni nomdlavuza.

Kungani ukhethe u-Israel ukuze uthole ukwelashwa kwe-CAR T-Cell?

Izindleko eziphansi zokwelashwa kwe-CAR T Cell e-China

Izindleko nokutholakala


Izindleko zokwelashwa kwe-CAR T-Cell kwa-Israel ziphansi kakhulu kunalezo zamazwe afana ne-US, UK, Australia, Japan, Korea kanye ne-Singapore. Ukwelashwa kwe-CAR T-Cell kwa-Israel kungabiza nje u-$75-100,000 USD. I-Israel inokutholakala okuphezulu ngokuqhathaniswa kwe-CAR T cell therapy. I-Israel isungule izikhungo nezibhedlela ezilapha izinhlobo ezahlukene zomdlavuza ngokwelashwa kwamaseli e-CAR-T. Lezi zikhungo kudala zenza lolu hlobo lokwelapha futhi ziyakwazi ukufinyelela nengqalasizinda namathuluzi eziwadingayo. Uma ukhetha ukuthi ungakuthola kuphi ukwelashwa kwamaseli e-CAR-T, kubalulekile ukucabanga ngokutholakala.

Isikhathi esifushane sokulinda


Uma imikhiqizo ye-CAR T-cell yenziwa endlini, inezinga lempumelelo elifanayo njenge-CAR yokuhweba eyenziwe yikhemisi, cishe awekho amaphutha okukhiqiza. Ukuphatha yonke inqubo esizeni kusho ukuthi isikhathi kusuka ku-leukapheresis kuya ekuphathweni kwe-CAR singancishiswa sibe yizinsuku ezingaba yi-10. Lokhu kusho ukuthi isiguli akudingeki sidlule ekwelashweni kwebhuloho, okuxhunyaniswa nemiphumela engcono. Kafushane isikhathi sokwelashwa sisonke sehlisa kuphela izinsuku ezingama-30 uma kuqhathaniswa nezinsuku ezingama-60-75 kwamanye amazwe.

 

Ubuchwepheshe bezokwelapha obusezingeni eliphezulu kwa-Israel

Ubuchwepheshe bezokwelapha obusezingeni eliphezulu


I-Israel yaziwa ngezifundo zayo zezokwelapha ezinhle kakhulu kanye nemibono emisha. Izwe lenze intuthuko ebalulekile ku-immunotherapy, okuhlanganisa nokwelashwa kwamaseli e-CAR-T. Odokotela nabahlengikazi bakwa-Israel bavame ukuba ngabokuqala ukuthuthukisa nokusebenzisa izindlela ezintsha zokwelapha, baqinisekise ukuthi iziguli zabo zithola ukunakekelwa okungcono kakhulu.

 

Ungasifaka kanjani isicelo sokwelashwa kwe-CAR T-Cell kwa-Israyeli?

Thumela imibiko yakho yezempilo ku info@cancerfax.com noma WhatsApp kubo +1-213 789-56-55 noma Shayela +91 96 1588 1588. Thumela imibiko elandelayo ukuze uthole umbono kanye nesilinganiso:

1) Isifinyezo sezokwelapha

2) Imibiko yegazi yakamuva

3) I-Biopsy

4) I-PET Scan yakamuva

5) I-biopsy yomnkantsha (Uma ikhona)

6) Noma yimiphi eminye imibiko efanele kanye nokuskena

Uma ithimba lethu seliyitholile imibiko yakho yezokwelashwa, siyayihlaziya futhi siyithumele ezibhedlela ezenza i-CAR T-Cell therapy ngalolo hlobo lomdlavuza nomaka. Sithumela imibiko kuchwepheshe othintekayo futhi sithole umbono wakhe. Siphinde sithole isilinganiso esivela esibhedlela ngokwelashwa okuphelele. Lokhu kukusiza ekuhleleleni sonke isikhathi sokwelashwa. 

Uma usunqume ukuvakashela ukwelashwa, sihlela incwadi ye-visa yezokwelapha kanye neminye imibhalo edingekayo evela esibhedlela. Siphinde sikusize futhi sikuqondise ekufakeni isicelo se-visa yezokwelapha ehhovisi lenxusa lakwa-Israel. Uma i-visa isilungile siyakusiza futhi sikuqondise ekulungiseleleni amathikithi ohambo nendiza. Futhi sihlela ihhotela lakho nendlu yezivakashi, uma kudingeka kwa-Israel. Lapho ufika edolobheni lokwelapha ummeleli wethu uzokwamukela esikhumulweni sezindiza.

Ummeleli wethu uzohlela ukuqokwa kukadokotela futhi agcwalise izinqubo ezidingekayo zokubhalisa kuwe. Uzokusiza futhi ngokulaliswa kwakho esibhedlela kanye nolunye usizo lwendawo nokwesekwa okudingekayo. Ngemva kokuphela kokwelashwa sizohlela ukuthi ulandelele ukubonisana nodokotela owelaphayo.

Izibhedlela eziphezulu ze-CAR T-Cell therapy kwa-Israel

Isibhedlela iSheba Tel Aviv Israel

ISaba Medical Centre


Ukwelashwa kwe-CAR T-cell, okwenziwa esibhedlela iSheba eTel Aviv, kwa-Israel, kuyigxathu elikhulu ebelapheni umdlavuza. Inika abantu abanezinhlobo ezithile zomdlavuza wegazi ithemba. NgesiHebheru, isibhedlela iSheba sibizwa ngeTel HaShomer. Isibhedlela esikhulu kunazo zonke kwa-Israel futhi sihola endaweni yokwelashwa kwe-CAR T-cell.
Isibhedlela iSheba sinamathuluzi aphambili nobuchwepheshe ukusiza ngokwelashwa kwe-CAR T-cell. Lesi sibhedlela sinamayunithi ayisipesheli asethwe ngobuchwepheshe bakamuva bokwenza amaseli. Lokhu kuqinisekisa ukuthi ama-T cell esiguli ngasinye enziwe ngokushesha nangokuphepha. Futhi, ithimba lodokotela nabahlengikazi eSibhedlela sase-Sheba banolwazi oluningi lokuqhuba izivivinyo zomtholampilo kanye nokufunda i-CAR T-cell therapy, esiza lo mkhakha uqhubeke uba ngcono.

THOLA UMBONO KANYE NESILINGANISO
Isibhedlela iSheba Tel Aviv Israel

Isikhungo Sezokwelapha iTel-Aviv Sourasky


I-Tel Aviv Sourasky Medical Center (Isibhedlela sase-Ichilov) yindawo lapho ungathola khona uhlobo olusha lokwelashwa olubizwa nge-car T-cell therapy. Kulokhu kwelashwa okusha, ama-T cell esiguli ayashintshwa ngokofuzo ukuze akwazi ukubona futhi ahlasele amangqamuzana omdlavuza. Umzimba wesiguli ube usugcwala la maseli ashintshiwe elebhu. Lapho, bangathola futhi babulale amangqamuzana omdlavuza. Uhlelo lweCar T-cell therapy e-Tel Aviv Sourasky Medical Center luqhutshwa ithimba lodokotela nochwepheshe be-immunotherapy abanolwazi oluningi. Iziguli ezinezinhlobo ezahlukene zomdlavuza zingaba nethemba ngalokhu kukhetha ukwelashwa okuthuthukisiwe, okubanikeza indlela yomuntu siqu nephumelelayo yokulwa nesifo.

THOLA UMBONO KANYE NESILINGANISO

Isikhungo Sezokwelapha saseHadassah


I-Hadassah Medical Centre eseJerusalema isenhliziyweni yendlela entsha yokwelapha umdlavuza ebizwa nge-Car T-cell therapy. I-Car T-cell therapy iyashintsha futhi ivule ama-T cell ukuze akwazi ukubona futhi alwe namaseli omdlavuza. Lokhu ikwenza ngokusebenzisa amandla amasosha omzimba esiguli. Iqembu elinekhono lodokotela nochwepheshe e-Hadassah basebenza ndawonye ukuze banikeze lokhu kwelashwa okuphambili. I-Hadassah Medical Center inikeza abantu abanezinhlobo ezahlukene zethemba lomdlavuza kanye nemiphumela engcono ngemishini yayo ephambili nokuzinikela emibonweni emisha. Ukwelashwa kwe-Car T-cell e-Hadassah kuyisibonelo esikhanyayo senqubekelaphambili emkhakheni we-oncology. Inikeza iziguli ukukhetha kokwelashwa komuntu siqu nokuhlosiwe.

THOLA UMBONO KANYE NESILINGANISO

Odokotela abaphezulu be-CAR T-Cell therapy kwa-Israel

Thatha umbono wesibili wochwepheshe ngokufakwa kokwelashwa kwe-CAR T-Cell kochwepheshe abahamba phambili be-CAR T-Cell therapy kwa-Israel. 

UDkt Arnon Nagler Hematologist kwa-Israel

UDkt. Arnon Nagler (MD, MSc)

Ukwelashwa kwe-CAR T-Cell

Iphrofayela: U-Arnon Nagler, usebenze iminyaka eminingi njengomqondisi wakho kokubili iDivision of Hematology kanye neBone Marrow Transplantation kanye neCord Blood Bank e-Chaim Sheba Medical Center, kanye noSolwazi Wezokwelapha e-The Tel Aviv University, kwa-Israel.

THOLA UMBONO KANYE NESILINGANISO
Prof_Amos_Toren_Sheba_Hospital

UDkt. Amos Toren (MD, PhD)

I-Hematology Yezingane

Iphrofayela: UProf. Amos Toren unguMqondisi we-Pediatric Hemato-Oncology kanye ne-BMT Division, othole isitifiketi ku-Pediatrics, General Hematology kanye ne-Pediatric Hemato-Oncology. Usebenze njengeNhloko yophiko lweHematology eSackler School of Medicine Tel-Aviv University amatemu ama-2.

THOLA UMBONO KANYE NESILINGANISO
UDkt. Ben Yehuda (MD, PhD)

UDkt. Ben Yehuda (MD, PhD)

Ukwelashwa kwe-CAR T-Cell

Iphrofayela: UProf. Dina Ben-Yehuda, inhloko yoMnyango Wezempilo Wenhlangano Yezokwelapha i-Hadassah, uqokwe njengoDini we-Hadassah-Hebrew University Faculty of Medicine–owesifazane wokuqala ukuba nalesi sikhundla. 

THOLA UMBONO KANYE NESILINGANISO

Zithini izindleko zokwelashwa kwe-CAR T-Cell kwa-Israel?

Izindleko zokwelashwa kwe-CAR T-Cell kwa-Israel ziqala kusuka ku-$75,000 USD kuye ngohlobo lwe-CAR T olukhethiwe. Ezindlekweni zokwelashwa kwe-CAR T ezikhulele ekhaya zizoba cishe ku-$80,000 USD kanti izindlela zokwelapha ezifana ne-Kymeriah ne-Breyanzi izindleko zingakhuphukela ku-$470,000 USD. Izindleko zokwelapha i-Car T-cell zingahluka kwa-Israel ngokusekelwe ezintweni eziningi, njengesikhungo sezokwelapha, uhlobo lomdlavuza olashwayo, kanye nempilo yesiguli. I-Car T-cell therapy iwukwelashwa okuyinkimbinkimbi futhi okukhethekile kakhulu okuhlanganisa ukushintsha izakhi zofuzo kanye nokunikeza isiguli ngasinye ukunakekela kwaso. Ngenxa yalokhu, kuyinqubo ebizayo. Ngokuvamile, izindleko zokwelashwa kwe-Car T-cell zifaka inqubo yobunjiniyela bofuzo, ukulaliswa esibhedlela, izinkokhelo zabasebenzi bezokwelapha, nokulandela umkhondo ngemva kokwelashwa. Iziguli kufanele zikhulume nabahlinzeki bazo bezempilo nezinkampani zomshwalense ukuze zithole ukuthi zingaba yini izindleko nokuthi hlobo luni losizo lwezezimali noma izinzuzo zomshwalense ezitholakalayo.

Kuyini ukwelashwa kwe-CAR T-Cell?

Ukwelashwa kwe-CAR-T-Cell eChina

I-Chimeric antigen receptor T-cell therapy, evame ukwaziwa ngokuthi i-CAR T-cell therapy, iwukwelapha okugoqa phansi okushintshe ngokuphelele indlela yokwelapha umdlavuza. Inikeza iziguli ezinomdlavuza othile ithemba ebekade libhekwa njengengelapheki noma kunezinye izindlela zokwelapha ezimbalwa.

Ukwelashwa kuhlanganisa ukusebenzisa amaseli omzimba esiguli—ikakhulukazi, ama-T cell—kanye nokuwashintsha ilebhu ukuze kuthuthukiswe amandla awo okuthola nokucekela phansi amangqamuzana omdlavuza. Ukwenza lokhu, ama-T cell anikezwa i-chimeric antigen receptor (CAR), ewanikeza amandla okukhomba amaprotheni athile, noma ama-antigen, ebusweni bamaseli omdlavuza.

Ama-T cell esiguli aqale akhishwe, bese eshintshwa izakhi zofuzo ukuze aveze i-CAR. Elabhorethri, la mangqamuzana ashintshiwe ayaphindaphindeka ukuze akhiqize inani elikhulu lamaseli e-CAR T, abese ebuyiselwa egazini lesiguli.

Isebenza kanjani ukwelashwa kwamaseli e-CAR T eChina

Ngokushesha nje lapho engaphakathi emzimbeni, amaseli e-CAR T athola amangqamuzana omdlavuza aveza i-antigen oyifunayo, anamathisele kuwo, futhi aqalise ukusabela okunamandla kokuzivikela komzimba. Amaseli e-CAR T acushiwe ayanda futhi ahlasele amangqamuzana omdlavuza, awabulale.

 

Isebenza kanjani ukwelashwa kwe-CAR T-Cell?

Isebenza kanjani i-CAR T Cell therapy eSingapore

Uma isetshenziselwa ukwelapha izifo ezithile zegazi njenge-acute lymphoblastic leukemia (ALL) kanye nezinhlobo ezithile ze-lymphoma, ukwelashwa kwe-CAR T-cell kubonise imiphumela engavamile. Ikhiqize izilinganiso zokusabela eziphawulekayo futhi kwezinye iziguli, ngisho nokukhululwa okuhlala isikhathi eside.

I-CAR T-cell therapy, nokho, iyindlela yokwelapha eyinkimbinkimbi neyingqayizivele engase ibe nezingozi nemiphumela emibi. I-Cytokine release syndrome (CRS), ukusabela kwe-immunology okusabalele okungase kubangele izimpawu ezifana nomkhuhlane futhi, ezimweni ezimbi kakhulu, ukwehluleka kwezitho, kungase kutholwe abantu abathile. Kubuye kube nemibiko yemiphumela emibi yemizwa, nokho ivamise ukulapheka.

Naphezu kwalobu bunzima, ukwelashwa kwe-CAR T-cell kuyintuthuko ebalulekile ekulweni nomdlavuza futhi kukhombisa amandla amakhulu ekusasa. Ucwaningo lwamanje lugxile ekuthuthukiseni ukusebenza kwayo kanye nephrofayili yokuphepha kanye nokwelula ukusetshenziswa kwayo ezinhlotsheni zomdlavuza ezihlukene. I-CAR T-cell therapy inamandla okushintsha ubuso bokwelashwa komdlavuza futhi inikeze iziguli yonke indawo ithemba elisha ngentuthuko eyengeziwe.

Lolu hlobo lokwelapha lubandakanya ukulungisa ama-T cell esiguli, uhlobo lwamangqamuzana omzimba omzimba, elebhu ukuze abophe futhi abulale amangqamuzana omdlavuza. Ishubhu lithutha igazi lisuka emthanjeni osengalweni yesiguli liye emshinini obizwa ngokuthi i-apheresis (ongabonisiwe), okhipha amangqamuzana amhlophe egazi, kuhlanganise nama-T cell, bese ubuyisela igazi elisele esigulini.
 
Amaseli e-T abe eseshintshwa ngofuzo elebhu ukuze aqukathe ufuzo lwesamukeli esiyingqayizivele eyaziwa ngokuthi i-chimeric antigen receptor (CAR). Amaseli e-CAR T aphindaphindeka elebhu ngaphambi kokuthi afakwe esigulini ngamanani amakhulu. I-antigen emangqamuzaneni omdlavuza ingabonwa ngamaseli e-CAR T, abese ebulala amangqamuzana omdlavuza.
 

Inqubo

Inqubo yokwelapha i-CAR-T, ethatha amasonto ambalwa, ibandakanya izinyathelo eziningi:

Ama-T cell akhishwa egazini lakho kusetshenziswa ishubhu elifakwa emthanjeni wengalo. Lokhu kuthatha amahora ambalwa.

Ama-T cell athuthelwa endaweni lapho enza khona ukuguqulwa kofuzo ukuze abe amaseli e-CAR-T. Kudlula amasonto amabili kuya kwamathathu kukho konke lokhu.

Amangqamuzana e-CAR-T abuyiselwa egazini lakho nge-drip. Lokhu kudinga amahora ambalwa.

Amaseli e-CAR-T aqondisa futhi aqede amangqamuzana omdlavuza kuwo wonke umzimba. Ngemva kokuthola ukwelashwa kwe-CAR-T, uzobhekwa eduze.

Hlobo luni lwamaseli omdlavuza olungelashwa nge-CAR-T Cell Therapy? 

Iziguli kuphela ezine-B-cell non-lymphoma Hodgkin's noma i-pediatric acute lymphoblastic leukemia esezizame izindlela zokwelapha ezivamile ezimbili ezingaphumelelanga okwamanje ezingasebenzisa imikhiqizo yokwelapha ye-CAR T-cell ethole imvume ye-FDA. Kodwa-ke, ukwelashwa kwe-CAR T-cell manje kuyahlolwa ezifundweni zomtholampilo njengokwelashwa komugqa wokuqala noma wesibili we-lymphoma yabantu abadala kanye ne-acute lymphoblastic leukemia yezingane. Muva nje, ezinye zezifundo zibonise impumelelo emangalisayo ezimeni zezimila eziqinile ezifana ne-glioblastoma, i-gliomas, umdlavuza wesibindi, umdlavuza wamaphaphu, umdlavuza we-GI, umdlavuza we-pancreatic kanye nomdlavuza womlomo.

Ukuphetha

Lokhu kubonisa intuthuko enkulu ekulawuleni i-leukemia kanye ne-B-cell lymphoma. Ukwengeza, kunikeza ithemba kulabo okwabikezelwa ukuthi ukuphila kwabo kuzohlala izinyanga eziyisithupha kuphela. Manje njengoba sesihlonze izindlela zokumelana futhi sakha amasu amaningi okulwa nazo, ikusasa libonakala lithembisa kakhulu.

Thintana nabahlinzeki bethu bezempilo abanolwazi olunzulu lapha ku ICancerFax ukuze uthole ukubonisana kwamahhala ukuze wenze uhlelo lokunakekelwa olufanele lwezidingo zakho zezempilo. Sicela uthumele imibiko yakho yezokwelashwa ku-info@cancerfax.com noma ku-WhatsApp + 1 213 789 56 55.

Yiziphi izinzuzo ze-CAR-T Cell Therapy?

Inzuzo eyinhloko ukuthi ukwelashwa kwe-CAR T-cell kudinga kuphela ukumnika okukodwa futhi ngokuvamile kudinga kuphela amasonto amabili okunakekelwa kwesiguli. Iziguli ezine-non-Hodgkin lymphoma kanye ne-leukemia yezingane ezisanda kutholwa, ngakolunye uhlangothi, ngokuvamile zidinga ukwelashwa ngamakhemikhali okungenani izinyanga eziyisithupha noma ngaphezulu.

Izinzuzo zokwelashwa kwe-CAR T-cell, empeleni okuwumuthi ophilayo, zingaphikelela iminyaka eminingi. Uma futhi kwenzeka ukuphindeka, amaseli asazokwazi ukukhomba futhi aqondise amaseli omdlavuza ngoba angaphila emzimbeni isikhathi eside. 

Nakuba ulwazi lusathuthuka, u-42% weziguli ze-lymphoma zabantu abadala ezathola ukwelashwa kwe-CD19 CAR T-cell zazisenoshwele ngemva kwezinyanga eziyi-15. Futhi ngemva kwezinyanga eziyisithupha, izingxenye ezimbili kwezintathu zeziguli ezine-acute lymphoblastic leukemia zazisaxole. Ngeshwa, lezi ziguli zinezimila ezinolaka kakhulu ezingazange zilashwe ngempumelelo kusetshenziswa izindinganiso zendabuko zokunakekela.

Hlobo luni lweziguli ezingaba ngabamukeli abahle be-CAR-T Cell Therapy?

Iziguli ezineminyaka ephakathi kwemi-3 kuya kwengu-70 zizanyiwe nge-CAR T-Cell yokwelapha izinhlobo ezahlukene zomdlavuza wegazi futhi kutholakale ukuthi iyasebenza kakhulu. Izikhungo eziningi ziye zafuna amanani empumelelo angaphezu kuka-80%. Umuntu ongcono kakhulu wokwelashwa kwe-CAR T-cell ngalesi sikhathi yingane ene-acute lymphoblastic leukemia noma umuntu omdala one-B-cell lymphoma enamandla osevele enemigqa emibili yokwelapha okungasebenzi. 

Ngaphambi kokuphela kuka-2017, lalingekho izinga elamukelekayo lokunakekela ezigulini esezidlule emigqeni emibili yokwelashwa ngaphandle kokuthola ukuxolelwa. Okuwukuphela kwendlela yokwelapha egunyazwe i-FDA kuze kube manje osekufakazele ukuthi kunenzuzo enkulu kulezi ziguli ukwelapha nge-CAR T-cell.

Kusebenza kahle kangakanani ukwelashwa kwamaseli e-CAR-T?

Ukwelashwa kwe-CAR T-cell kube yimpumelelo kakhulu ekwelapheni ezinye izinhlobo zomdlavuza wegazi, njenge-acute lymphoblastic leukemia (ALL) kanye ne-non-Hodgkin lymphoma. Ezivivinyweni zemitholampilo, amazinga okuphendula abe mahle kakhulu, futhi iziguli eziningi ziye zangena ekwelashweni okuphelele. Kwezinye izimo, abantu ababezame yonke eminye imithi baba nokukhululwa okuhlala isikhathi eside noma ngisho nokwelashwa okungenzeka.

Enye yezinto ezinhle kakhulu ngokwelashwa kwe-CAR T-cell ukuthi iqondise kumaseli afanele. Ama-receptor e-CAR angezwe kuma-T cell angathola amamaki athile kumaseli omdlavuza. Lokhu kwenza kube nokwenzeka ukunikeza ukwelashwa okuhlosiwe. Le ndlela ehlosiwe ilimaza amaseli anempilo kancane ngangokunokwenzeka futhi yehlisa ubungozi bemiphumela engemihle eza nokwelashwa kwendabuko okufana nokwelapha ngamakhemikhali.

Kodwa kubalulekile ukukhumbula ukuthi ukwelashwa kwe-CAR T-cell kuseyindawo entsha esashintsha. Abacwaningi nodokotela basebenza kanzima ukuxazulula izinkinga ezifana nezindleko eziphezulu, amathuba okuba nemiphumela emibi kakhulu, kanye neqiniso lokuthi kusebenza kuphela ezinhlotsheni ezithile zomdlavuza.

Ekugcineni, ukwelashwa kwe-CAR T-cell kubonise ukuthi kuyindlela ephumelela kakhulu yokwelapha ezinye izinhlobo zomdlavuza wegazi. Noma kuyindlela ethembisayo nenamandla, ucwaningo olwengeziwe nezivivinyo zomtholampilo ziyadingeka ukuze kuthuthukiswe futhi kutholwe izindlela ezintsha zokuyisebenzisa. Ukwelashwa kwe-CAR T-cell kungashintsha indlela umdlavuza welashwa ngayo futhi kwenze izinto zibe ngcono kubantu emhlabeni wonke uma uqhubeka nokuba ngcono.

Imibandela yokufakwa nokukhipha

Indlela yokufakwa yokwelashwa kwe-CAR T-cell:

1. Iziguli ezine-CD19 + B-cell Lymphoma (Okungenani ukuhlanganiswa kwangaphambili okungu-2 imiphumela emibi yokwelashwa ngamakhemikhali izinhlobo)

2.Ukuba neminyaka eyi-3 kuye kwengama-75

3. Isilinganiso se-ECOG ≤2

4. Abesifazane abanamandla okuthola izingane kumele bathathwe ukuhlolwa komchamo wokukhulelwa futhi kutholakale ukuthi abanalo ngaphambi kokwelapha. Zonke iziguli ziyavuma ukusebenzisa izindlela ezithembekile zokuvimbela inzalo ngesikhathi sesilingo kuze kube kulandelwa okokugcina.

Imibandela yokungafakwa yokwelashwa kwe-CAR T-cell:

1.Ukuphakama komfutho wegazi ophakeme noma ukuquleka

2. Ukwehluleka kokuphefumula

3. Kusatshalaliswe i-coagulation ye-intravascular

4. I-Hematosepsis noma ukutheleleka okusebenzayo okungalawulwa

5. Isifo sikashukela esingalawuleki.

Izindlela zokwelapha ze-CAR T-Cell zigunyazwe yi-USFDA

I-B-cell precursor acute lymphoblastic leukemia, ebuyele emuva noma i-refractory isakaza i-B-cell lymphoma enkulu

Izinga lokuphendula eliphelele (CR): >90%

Ithagethi: CD19

Price: $ 475,000

Isikhathi sokugunyaza: Agasti 30, 2017

I-B-cell lymphoma enkulu ebuyele emuva noma ephikisayo, ebuyele emuva noma ephikisayo ye-follicular cell lymphoma.

Izinga lokuphendula eliphelele le-Non-Hodgkin's lymphoma (CR): 51%

Ithagethi: CD19

Price: $ 373,000

Isikhathi sokugunyazwa: 2017 Okthoba 18

I-B-cell lymphoma ebuyiselwe emuva noma ephikisayo

I-Mantle cell lymphoma Izinga lokuphendula eliphelele (CR): 67%

Ithagethi: CD19

Price: $ 373,000

Isikhathi esivunyelwe: Okthoba 18, 2017

I-B-cell lymphoma ebuyiselwe emuva noma ephikisayo

Izinga lokuphendula eliphelele (CR): 54%

Ithagethi: CD19
Price: $ 410,300

Isikhathi esivunyelwe: Okthoba 18, 2017

I-Myeloma Ephindaphindekayo noma Ephikisayo 

Izinga lokuphendula eliphelele: 28%

Ithagethi: CD19
Price: $ 419,500
Kuvunyelwe: Okthoba 18, 2017

Iyini imiphumela emibi yokwelashwa kwe-CAR-T Cell?

Okubalulwe ngezansi eminye yemiphumela emibi yokwelashwa kwe-CAR T-Cell.

  1. I-Cytokine release syndrome (CRS): Umthelela oseceleni ovame kakhulu futhi okungenzeka ubaluleke kakhulu wokwelashwa kwe-CAR T-cell i-cytokine release syndrome (CRS). Izimpawu ezinjengomkhuhlane, okuhlanganisa imfiva, ukukhathala, ikhanda elibuhlungu, nobuhlungu bemisipha, zibangelwa ukukhiqizwa kwama-T cell ashintshiwe ama-cytokines. Ezimweni ezimbi kakhulu, i-CRS ingase ibangele izinga lokushisa eliphezulu, i-hypotension, ukwehluleka kwezitho, ngisho nemiphumela engase ibulale. 
  2. Ubuthi Bezinzwa: Ezinye iziguli zingase zibe nemiphumela engemihle yemizwa, engase ihluke kakhulu kusukela kuzimpawu ezingathí sina njengokudideka okuncane kanye nokudideka kuye kwezibucayi kakhulu njengokuquleka, ukudangala, kanye ne-encephalopathy. Ngemuva kokujova i-CAR T-cell, ubuthi bezinzwa buvame ukwenzeka phakathi nesonto lokuqala. 
  3. I-Cytopenias: Ukwelashwa kwe-CAR T-cell kungabangela ukubala okuphansi kwamangqamuzana egazi, njenge-anemia (isibalo esiphansi samangqamuzana egazi abomvu), i-neutropenia (isibalo esiphansi samangqamuzana egazi amhlophe), kanye ne-thrombocytopenia (isibalo esiphansi seplatelet). Ukutheleleka, ukopha, nokukhathala kuphakathi kwezingozi ezingabhebhethekiswa yilezi cytopenias. 
  4. Amagciwane: Ukucindezela kwe-CAR T-cell therapy kwamangqamuzana omzimba anempilo kwandisa ingozi yokutheleleka ngamagciwane, igciwane, kanye nesikhunta. Ukuze kuvinjwe izifo, iziguli kungase kudingeke ukuthi zibhekwe ngeso elibukhali futhi zinikezwe imithi yokuzivikela.
  5. I-Tumor Lysis Syndrome (TLS): Ngemva kokwelashwa kwe-CAR T-cell, kwezinye izimo kuyenzeka ukuthi amanani amakhulu wokuqukethwe kweseli akhishelwe egazini ngenxa yokubulawa ngokushesha kwamaseli esimila. Lokhu kungase kubangele ukuphazamiseka kwezinqubo ze-metabolic, okufana namazinga e-potassium eningi, i-uric acid, ne-phosphate, okungase kulimaze izinso futhi kubangele nezinye izinkinga. 
  6. I-Hypogammaglobulinemia: Ukwelashwa kwe-CAR T-cell kunamandla okunciphisa ukwakheka kwe-antibody, okungase kubangele i-hypogammaglobulinemia. Lokhu kungase kwenze izifo eziphindelelayo zibe nokwenzeka kakhulu futhi kubize ukuqhubeka kwemithi yokubuyisela amasosha omzimba. 
  7. Ubuthi Bomzimba: I-CAR T-cell therapy inamandla okulimaza izitho eziningi, okuhlanganisa inhliziyo, amaphaphu, isibindi, nezinso. Lokhu kungase kuholele ekuhlolweni kokusebenza okungavamile kwezinso, izinkinga zokuphefumula, izinkinga zenhliziyo, nokuhlolwa kokusebenza okungavamile kwesibindi.
  8. I-Hemophagocytic lymphohistiocytosis (HLH): Isifo esingandile kodwa esibulalayo esibizwa ngokuthi i-hemophagocytic lymphohistiocytosis (HLH) singakhula ngenxa yokwelashwa kwe-CAR T-cell. Kuhilela ukusebenza ngokweqile kwamangqamuzana omzimba omzimba, okubangela ukulimala okukhulu kwezitho nokuvuvukala.
  9. I-Hypotension kanye nokugcinwa koketshezi: Njengomphumela wama-cytokines akhishwa amaseli e-CAR T, ezinye iziguli zingase zibe nomfutho wegazi ophansi (hypotension) nokugcinwa koketshezi. Ukubhekana nalezi zimpawu, kungase kudingeke izinyathelo ezisekelayo ezihlanganisa uketshezi olufakwa emthanjeni nezidakamizwa.
  10. Izifo Zesibili: Imibiko yezifo zesibili ezibulalayo ezivela ngemva kokwelashwa kwe-CAR T-cell ikhona, kungakhathaliseki ukuthi inqabile. Njengamanje ucwaningo luyenziwa mayelana namathuba ezifo zesibili kanye nezingozi zesikhathi eside.

Kubalulekile ukukhumbula ukuthi akusona sonke isiguli esizoba nale miphumela engemihle, nokuthi izinga lomuntu ngamunye lokuzwela lizohluka. Ukuze kuncishiswe futhi kuncishiswe le miphumela emibi engaba khona, ithimba lezokwelapha lihlolisisa iziguli ngaphambi, phakathi, nangemuva kokwelashwa kwe-CAR T-cell.

Ubude besikhathi

Bheka ngezansi kwengqikithi yesikhathi esidingekayo ukuze uqedele inqubo yokwelapha ye-CAR T-Cell. Nakuba isikhathi sincike kakhulu ebangeni lelebhu esuka esibhedlela elungise i-CAR.

  1. Ukuhlolwa nokuhlolwa: isonto elilodwa
  2. Ukwelashwa kwangaphambili & Ukuqoqwa kwe-T-Cell: isonto elilodwa
  3. Ukulungiswa kwe-T-Cell nokubuyisela: amasonto amabili-amathathu
  4. Ukuhlaziywa kwe-1st Ukusebenza kahle: amaviki amathathu
  5. Ukuhlaziywa kwe-2nd Ukusebenza kahle: amaviki amathathu.

Isikhathi esiphelele: 10-12 Amaviki

Okwakamuva kumdlavuza 

Indlela Ukwelapha Okuhlosiwe Kuyiguqula Kanjani Ukwelashwa Komdlavuza Okuthuthukile

Ngabe Ukwelashwa Okuhlosiwe Kuguqula Kangakanani Ukwelashwa Komdlavuza Okuthuthukile?

April 25, 2024 Awekho amazwana

Emkhakheni we-oncology, ukuvela kokwelashwa okuhlosiwe kuye kwaguqula isimo sokwelashwa komdlavuza oseqophelweni eliphezulu. Ngokungafani ne-chemotherapy evamile, eqondisa kabanzi amangqamuzana ahlukanisa ngokushesha, ukwelashwa okuhlosiwe kuhloswe ukuhlasela amangqamuzana omdlavuza ngokukhetha kuyilapho kunciphisa umonakalo kumaseli avamile. Le ndlela enembayo yenziwa yenzeke ngokuhlonza izinguquko ezithile zamangqamuzana noma ama-biomarker ahlukile kumaseli omdlavuza. Ngokuqonda amaphrofayili amangqamuzana ezimila, izazi ze-oncologists zingakwazi ukuhlanganisa izindlela zokwelapha ezisebenza kahle kakhulu futhi ezinobuthi obuncane. Kulesi sihloko, sihlolisisa izimiso, izinhlelo zokusebenza, kanye nentuthuko yokwelapha okuhlosiwe kumdlavuza othuthukile.

Funda kabanzi "
I-CAR T Ukwelashwa Kwamaseli e-AIDS ehlobene ne-B Cell malignancies

I-CAR T Cell therapy ye-AIDS ehlobene ne-B-Cell malignancies

April 18, 2024 Awekho amazwana

Ukwelashwa kwamaseli e-CAR T okulimaza amangqamuzana e-B ahlobene ne-HIV kuhilela ukushintsha ngokofuzo ama-T cell esiguli ukuze aveze ama-chimeric antigen receptors (CARs) aqondise i-CD19 kuma-B cell. Lokhu kwelashwa kunesithembiso ekuqedeni amaseli B ayingozi kodwa kufanele kulawule ngokucophelela ukuvinjelwa kwamasosha omzimba kubantu abane-HIV.

Funda kabanzi "
Izibalo zomdlavuza e-India 2024

Izibalo zomdlavuza eNdiya 2024: Izehlakalo, izilinganiso kanye nokuqagela

April 10, 2024 Awekho amazwana

Ngo-2024, umdlavuza uzohlala uyinselelo enkulu yezempilo eNdiya. Izwe libona amacala amasha angaphezu kwezigidi eziyi-1.5 ngonyaka. Umdlavuza wamabele nowomlomo wande kakhulu kwabesifazane nabesilisa, ngokulandelana. Ngokudabukisayo, izimo eziningi zitholwa sekwephuzile, okunomthelela emazingeni okusinda. Ukuqwashisa okuthuthukisiwe kanye nokufinyelela ekunakekelweni kwezempilo kubalulekile. Ngo-2030, izigameko zomdlavuza kulindeleke ukuthi zidlule izigameko eziyizigidi eziyi-1.7 ngonyaka. Imizamo yokuthuthukisa ukuvikela, ukutholwa kusenesikhathi, kanye nokufinyelela ekwelashweni kubalulekile ukuze kuncishiswe lo mthwalo okhulayo. Bheka izibalo zethu zomdlavuza eNdiya zika-2024 kanye nokuqagela okuzayo.

Funda kabanzi "
Qala ingxoxo
Siku-inthanethi! Xoxa Nathi!
Skena ikhodi
Sawubona,

Siyakwamukela kuCancerFax!

Ukwelashwa kwe-CAR T-Cell kwa-Israel kubiza phakathi kuka-75,000 no-90,000 USD, kuye ngohlobo nesigaba sesifo kanye nesibhedlela esikhethiwe.

Sisebenza nezibhedlela ezingcono kakhulu ze-hematology kwa-Israyeli. Sicela usithumelele imibiko yakho yezokwelashwa, futhi sizobuyela kuwe nemininingwane yokwelashwa, isibhedlela, kanye nesilinganiso sezindleko.

Xoxa ukuze uthole okwengeziwe>